Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

588
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
588
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

996
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
996
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

698
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
698
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

4.7K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

744
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.5K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BACT-URIE: A Novel Score Integrating Bacteriuria to Predict Infective Endocarditis in Patients With <i>Staphylococcus aureus</i> Bacteremia.

Open forum infectious diseases·2026
Same author

Evaluation of the STANDARD M10 and Xpert <i>C. difficile</i> assays for the detection of toxigenic <i>Clostridioides difficile</i> in stools.

Microbiology spectrum·2026
Same author

Value of molecular biology tests in community-acquired acute pneumonia.

Infectious diseases now·2025
Same author

Revue des maladies respiratoires·2025
Same author

Corrigendum to "Update of guidelines for management of community acquired pneumonia in adults by the French infectious disease society (SPILF) and the French-speaking society of respiratory diseases (SPLF). Endorsed by the French intensive care society (SRLF), the French microbiology society (SFM), the French radiology society (SFR) and the French emergency society (SFMU)" [IDNOW 55/2 (2025) 105034].

Infectious diseases now·2025
Same author

[Update of guidelines for management of Community Acquired pneumonia in adults by French Infectious Disease Society (SPILF) and the French Speaking Society of Respiratory Diseases (SPLF). Endorsed by French intensive care society (SRLF), French microbiology society (SFM), French radiology society (SFR), French emergency society (SFMU)].

Revue des maladies respiratoires·2025
Same journal

[Etiology and clinical expression of angina].

Medecine et maladies infectieuses·2024
Same journal

[Rational use of antibiotics treatment in acute bronchitis].

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
Same journal

[Detection of human rotaviruses in faeces : comparison of five methods].

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
See all related articles

Related Experiment Video

Updated: Apr 25, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K

Update on Clostridium difficile infections.

A Le Monnier1, J-R Zahar2, F Barbut3

  • 1Unité de microbiologie clinique, groupe hospitalier Paris Saint-Joseph, 185, rue Raymond-Losserand, 75014 Paris, France; Université Paris-Sud, EA4043 écosystème microbien digestif et santé, 92296 Châtenay-Malabry cedex, France.

Medecine Et Maladies Infectieuses
|August 27, 2014
PubMed
Summary
This summary is machine-generated.

Clostridium difficile infections (CDI) are increasingly severe and widespread, driven by new strains. Advances in diagnostics and novel therapies offer hope for managing this challenging infection.

Keywords:
Clostridium difficileColiteColitisDiarrhée post-antibiotiquePost-antibiotic diarrhea

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.0K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.2K

Related Experiment Videos

Last Updated: Apr 25, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.0K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.2K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Clostridium difficile infections (CDI) are a significant healthcare burden, particularly in hospitalized patients using antibiotics.
  • CDI epidemiology has shifted, with increased frequency, severity, and spread due to hypervirulent strains like 027/NAP1/BI.
  • Host immune response is critical in CDI pathogenesis and severity, influencing recurrent or severe forms.

Purpose of the Study:

  • To review the changing epidemiology of CDI.
  • To discuss advancements in diagnostic strategies and treatment guidelines.
  • To highlight emerging therapeutic options for CDI.

Main Methods:

  • Review of current literature on Clostridium difficile infections.
  • Analysis of epidemiological trends and diagnostic advancements.
  • Evaluation of established and novel treatment strategies.

Main Results:

  • CDI incidence is linked to clinical suspicion and screening frequency.
  • New molecular diagnostic tests (NAAT) simplify CDI diagnosis.
  • Oral metronidazole is recommended for mild/moderate CDI, vancomycin for severe cases.

Conclusions:

  • Management of recurrent CDI remains a challenge.
  • Innovative therapies including fecal transplantation, monoclonal antibodies, and vaccination show promise.
  • Updated diagnostic and therapeutic approaches are crucial for controlling CDI.